Himasa Faiza Idris, Singhal Manmohan, Ojha Abhijeet, Kumar Bhavna
Faculty of Pharmacy, DIT University, Dehradun 248009, Uttarakhand, India.
College of Pharmacy, Six Sigma Institute of Technology, Rudrapur, Uttarakhand, India.
Curr Pharm Des. 2022;28(7):560-569. doi: 10.2174/1381612827666211115154907.
Diabetic retinopathy is a posterior eye disorder in which damage occurs to the light sensitive retina due to diabetes mellitus. This disorder specifically affects people aged between 18-64 with type ІІ diabetes. This disease progresses through different pathophysiological pathways, which include oxidative stress, inflammation, stimulation of the growth factor in the eye's vasculature, isoforms of protein kinase C, and also the activation of the hexosamine pathway. It starts as micro aneurysms and advances in complicated stage, which results in retinal detachment. Treatment of posterior eye diseases has complications due to the structural design of the eye and physiological barriers present. The current treatment approach involves the use of intravitreal anti- VEGFs, corticosteroids implants, laser and surgery; these treatment methods have drawbacks attributed to them despite their benefits. The development of a robust delivery system with minimal or no invasion to tackle the issues of diabetic retinopathy will be of considerable benefit to patients having diabetic retinopathy; the dependency on ophthalmologists for multiple injections will significantly reduce and provide a promising approach in drug delivery. In this review article, the authors provided information related to existing treatment methods available for diabetic retinopathy, the most significant among which is nanotechnology approach through which local delivery via the ocular route to posterior eye can be achieved. It also possesses the various carriers studied for the non-invasive approach for retinal delivery of medicaments. Non-invasive approach for delivery of drugs can be considered as potential for the treatment of diabetic retinopathy.
糖尿病视网膜病变是一种眼部后部疾病,由于糖尿病导致对光敏感的视网膜受损。这种疾病特别影响年龄在18 - 64岁之间的II型糖尿病患者。该疾病通过不同的病理生理途径发展,包括氧化应激、炎症、眼部血管系统中生长因子的刺激、蛋白激酶C的同工型,以及己糖胺途径的激活。它始于微动脉瘤,并发展到复杂阶段,导致视网膜脱离。由于眼睛的结构设计和存在的生理屏障,眼部后部疾病的治疗存在并发症。目前的治疗方法包括使用玻璃体内抗血管内皮生长因子(anti-VEGFs)、皮质类固醇植入物、激光和手术;尽管这些治疗方法有好处,但也有其缺点。开发一种侵入性最小或无侵入的强大给药系统来解决糖尿病视网膜病变问题,将对患有糖尿病视网膜病变的患者有很大益处;对眼科医生进行多次注射的依赖将显著降低,并为药物递送提供一种有前景的方法。在这篇综述文章中,作者提供了与糖尿病视网膜病变现有治疗方法相关的信息,其中最重要的是纳米技术方法,通过该方法可以实现经眼部途径向眼后部的局部递送。它还拥有为药物视网膜递送的非侵入性方法研究的各种载体。药物递送的非侵入性方法可被视为治疗糖尿病视网膜病变的潜力。